Incretins: their physiology and application in the treatment of diabetes mellitus. (Q38225693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Incretins: their physiology and application in the treatment of diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Hale M Tasyurek

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hasan Ali Altunbas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Salih Sanlioglu

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

Diabetes - Metabolism: Research and Reviews

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

354-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24989141%20AND%20SRC:MED&resulttype=core&format=json

AACE Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice

21 March 2020

cites work

1 reference

Clinical utility of insulin and insulin analogs

21 January 2018

1 reference

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

21 January 2018

1 reference

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

21 January 2018

1 reference

Insulin gene therapy from design to beta cell generation.

21 January 2018

1 reference

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity

21 January 2018

1 reference

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor

21 January 2018

1 reference

Therapeutic potential of VIP vs PACAP in diabetes

21 January 2018

1 reference

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

21 January 2018

1 reference

cAMP-GEFII is a direct target of cAMP in regulated exocytosis

21 January 2018

1 reference

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.

21 January 2018

1 reference

beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.

21 January 2018

1 reference

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass

21 January 2018

1 reference

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

21 January 2018

1 reference

Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.

21 January 2018

1 reference

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors

21 January 2018

1 reference

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

21 January 2018

1 reference

Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

21 January 2018

1 reference

Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow

21 January 2018

1 reference

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

21 January 2018

1 reference

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

21 January 2018

1 reference

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling

21 January 2018

1 reference

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

21 January 2018

1 reference

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

21 January 2018

1 reference

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.

21 January 2018

1 reference

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes

21 January 2018

1 reference

Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons

21 January 2018

1 reference

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

On the physiology of GIP and GLP-1.

21 January 2018

1 reference

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

21 January 2018

1 reference

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117.

21 January 2018

1 reference

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

21 January 2018

1 reference

Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice

21 January 2018

1 reference

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

21 January 2018

1 reference

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

21 January 2018

1 reference

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet

21 January 2018

1 reference

Vaccination against GIP for the treatment of obesity

21 January 2018

1 reference

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

21 January 2018

1 reference

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

21 January 2018

1 reference

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

21 January 2018

1 reference

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

21 January 2018

1 reference

GPR119: "double-dipping" for better glycemic control

21 January 2018

1 reference

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives

21 January 2018

1 reference

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia

21 January 2018

1 reference

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

21 January 2018

1 reference

The biology of incretin hormones

21 January 2018

1 reference

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes

21 January 2018

1 reference

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

Pancreatitis: a potential complication of liraglutide?

21 January 2018

1 reference

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

Acute pancreatitis associated with liraglutide.

21 January 2018

1 reference

Association of pancreatitis with glucagon-like peptide-1 agonist use.

21 January 2018

1 reference

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

21 January 2018

1 reference

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?

21 January 2018

1 reference

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

GLP-1-based therapy for diabetes: what you do not know can hurt you.

21 January 2018

1 reference

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia

21 January 2018

1 reference

GLP-1 receptor agonist effects on normal and neoplastic pancreata

21 January 2018

1 reference

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604

21 January 2018

1 reference

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

21 January 2018

1 reference

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006.

21 January 2018

1 reference

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

Do GLP-1-based therapies increase cancer risk?

21 January 2018

1 reference

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.

21 January 2018

1 reference

A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

21 January 2018

1 reference

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

21 January 2018

1 reference

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

21 January 2018

1 reference

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

21 January 2018

1 reference

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

21 January 2018

1 reference

By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012

21 January 2018

1 reference

7 January 2021

Global prevalence and future of diabetes mellitus.

1 reference

7 January 2021

Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011

1 reference

7 January 2021

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

1 reference

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

7 January 2021

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

7 January 2021

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop

1 reference

7 January 2021

Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells

1 reference

7 January 2021

Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?)

1 reference

7 January 2021

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

1 reference

7 January 2021

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

7 January 2021

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice.

1 reference

7 January 2021

Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat

1 reference

7 January 2021

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

7 January 2021

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

7 January 2021

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate)

1 reference

7 January 2021

Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects

1 reference

7 January 2021

GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1

1 reference

7 January 2021

A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release

1 reference

7 January 2021

Collateral damage: the conundrum of drug safety

1 reference

7 January 2021